|
DE3303707A1
(de)
|
1983-02-04 |
1984-08-09 |
Dynamit Nobel Ag, 5210 Troisdorf |
Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen
|
|
US5033252A
(en)
|
1987-12-23 |
1991-07-23 |
Entravision, Inc. |
Method of packaging and sterilizing a pharmaceutical product
|
|
US5052558A
(en)
|
1987-12-23 |
1991-10-01 |
Entravision, Inc. |
Packaged pharmaceutical product
|
|
JPH01167840A
(ja)
|
1987-12-24 |
1989-07-03 |
Konica Corp |
新規な写真用シアンカプラー
|
|
US5323907A
(en)
|
1992-06-23 |
1994-06-28 |
Multi-Comp, Inc. |
Child resistant package assembly for dispensing pharmaceutical medications
|
|
GB9226855D0
(en)
|
1992-12-23 |
1993-02-17 |
Erba Carlo Spa |
Vinylene-azaindole derivatives and process for their preparation
|
|
US6326469B1
(en)
|
1994-04-22 |
2001-12-04 |
Sugen, Inc. |
Megakaryocytic protein tyrosine kinases
|
|
US5593997A
(en)
|
1995-05-23 |
1997-01-14 |
Pfizer Inc. |
4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
|
|
CH690773A5
(de)
|
1996-02-01 |
2001-01-15 |
Novartis Ag |
Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
|
|
AU3176297A
(en)
|
1996-06-25 |
1998-01-14 |
Novartis Ag |
Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
|
|
TR199902301T2
(xx)
|
1997-03-19 |
1999-12-21 |
Basf Aktiengesellschaft |
Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
|
|
ATE364374T1
(de)
*
|
1997-08-11 |
2007-07-15 |
Pfizer Prod Inc |
Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
|
|
WO1999033467A1
(en)
*
|
1997-12-31 |
1999-07-08 |
Choongwae Pharma Corporation |
Method and composition of an oral preparation of itraconazole
|
|
DE69918089T2
(de)
|
1998-04-17 |
2005-07-14 |
Parker Hughes Institute, St. Paul |
Btk inhibitoren und verfahren zur identifizierung und verwendung
|
|
US6303652B1
(en)
|
1998-08-21 |
2001-10-16 |
Hughes Institute |
BTK inhibitors and methods for their identification and use
|
|
US6998233B2
(en)
|
1998-06-26 |
2006-02-14 |
Sunesis Pharmaceuticals, Inc. |
Methods for ligand discovery
|
|
US20050287596A9
(en)
|
1998-06-26 |
2005-12-29 |
Braisted Andrew C |
Novel ligands and libraries of ligands
|
|
US6335155B1
(en)
|
1998-06-26 |
2002-01-01 |
Sunesis Pharmaceuticals, Inc. |
Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
|
|
UA74141C2
(uk)
|
1998-12-09 |
2005-11-15 |
Дж.Д. Сірл Енд Ко. |
Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
|
|
ES2307482T3
(es)
*
|
1999-02-10 |
2008-12-01 |
Pfizer Products Inc. |
Dispersiones farmaceuticas solidas.
|
|
US6306897B1
(en)
|
1999-03-19 |
2001-10-23 |
Parker Hughes Institute |
Calanolides for inhibiting BTK
|
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
|
EP1212327B8
(en)
|
1999-09-17 |
2004-02-25 |
Abbott GmbH & Co. KG |
Pyrazolopyrimidines as therapeutic agents
|
|
ATE277044T1
(de)
|
1999-10-06 |
2004-10-15 |
Boehringer Ingelheim Pharma |
Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
|
|
US6506769B2
(en)
|
1999-10-06 |
2003-01-14 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic compounds useful as inhibitors of tyrosine kinases
|
|
JP2003516351A
(ja)
|
1999-11-30 |
2003-05-13 |
パーカー ヒューズ インスティテュート |
コラーゲン誘導血小板凝集阻害剤
|
|
AU2439701A
(en)
|
1999-12-17 |
2001-06-25 |
Ariad Pharmaceuticals, Inc. |
Novel heterocycles
|
|
GB0005345D0
(en)
|
2000-03-06 |
2000-04-26 |
Mathilda & Terence Kennedy Ins |
Methods of treating sepsis septic shock and inflammation
|
|
GB0108903D0
(en)
|
2000-10-05 |
2001-05-30 |
Aventis Pharm Prod Inc |
Novel crystalline forms of a factor Xa inhibitor
|
|
EP1373554A2
(en)
|
2000-10-23 |
2004-01-02 |
Bristol-Myers Squibb Company |
Modulators of bruton's tyronsine kinase, their identification and use
|
|
CA2436570A1
(en)
|
2000-12-06 |
2002-06-13 |
Pharmacia Corporation |
Rapidly dispersing pharmaceutical composition comprising effervescent agents
|
|
KR20030077042A
(ko)
*
|
2001-02-27 |
2003-09-29 |
아스트라제네카 아베 |
비칼루타마이드를 포함하는 약학 제제
|
|
MXPA03008560A
(es)
|
2001-03-22 |
2004-06-30 |
Abbot Gmbh & Co Kg |
Pirazolopirimidinas como agentes terapeuticos.
|
|
US8306897B2
(en)
|
2001-05-04 |
2012-11-06 |
Stockshield, Inc. |
Method and system for insuring against investment loss
|
|
WO2003000187A2
(en)
|
2001-06-21 |
2003-01-03 |
Ariad Pharmaceuticals, Inc. |
Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
|
|
WO2003014732A1
(en)
|
2001-08-10 |
2003-02-20 |
Symyx Technologies, Inc. |
Apparatuses and methods for creating and testing pre-formulations and systems for same
|
|
CA2810339A1
(en)
|
2001-08-10 |
2003-02-20 |
Novartis Ag |
Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
|
|
WO2003016338A1
(en)
|
2001-08-15 |
2003-02-27 |
Parker Hughes Institute |
Crystal structure of the btk kinase domain
|
|
JP4391237B2
(ja)
|
2001-11-21 |
2009-12-24 |
サネシス ファーマシューティカルズ, インコーポレイテッド |
リガンド発見のための方法
|
|
US20050084905A1
(en)
|
2002-03-21 |
2005-04-21 |
Prescott John C. |
Identification of kinase inhibitors
|
|
GB2388594A
(en)
|
2002-05-16 |
2003-11-19 |
Bayer Ag |
Imidazo-triazine PDE 4 inhibitors
|
|
CA2494942A1
(en)
|
2002-08-08 |
2004-02-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Substituted benzimidazole compounds
|
|
GB0303910D0
(en)
|
2003-02-20 |
2003-03-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
|
US7687506B2
(en)
|
2003-04-11 |
2010-03-30 |
The Regents Of The University Of California |
Selective serine/threonine kinase inhibitors
|
|
WO2004100868A2
(en)
|
2003-04-23 |
2004-11-25 |
Abbott Laboratories |
Method of treating transplant rejection
|
|
EP1473039A1
(en)
|
2003-05-02 |
2004-11-03 |
Centre National De La Recherche Scientifique (Cnrs) |
Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
|
|
US7405295B2
(en)
|
2003-06-04 |
2008-07-29 |
Cgi Pharmaceuticals, Inc. |
Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
|
|
US7393848B2
(en)
|
2003-06-30 |
2008-07-01 |
Cgi Pharmaceuticals, Inc. |
Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
|
|
SI1663217T1
(sl)
*
|
2003-08-29 |
2010-10-29 |
Lifecycle Pharma As |
Trdne disperzije, ki vsebujejo takrolimus
|
|
US8131475B2
(en)
|
2003-09-03 |
2012-03-06 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Methods for identifying, diagnosing, and predicting survival of lymphomas
|
|
CN1897950A
(zh)
|
2003-10-14 |
2007-01-17 |
惠氏公司 |
稠合芳基和杂芳基衍生物及其使用方法
|
|
ATE525377T1
(de)
|
2003-10-15 |
2011-10-15 |
Osi Pharm Inc |
Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
|
|
US20070196395A1
(en)
|
2003-12-12 |
2007-08-23 |
Mackerell Alexander |
Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
|
|
US20050153990A1
(en)
|
2003-12-22 |
2005-07-14 |
Watkins William J. |
Phosphonate substituted kinase inhibitors
|
|
US20070281907A1
(en)
|
2003-12-22 |
2007-12-06 |
Watkins William J |
Kinase Inhibitor Phosphonate Conjugates
|
|
CN1934113B
(zh)
|
2004-01-26 |
2011-11-09 |
沃泰克斯药物股份有限公司 |
可用作蛋白激酶抑制剂的组合物
|
|
CA2553724A1
(en)
|
2004-02-03 |
2005-08-18 |
Abbott Laboratories |
Aminobenzoxazoles as therapeutic agents
|
|
ITMI20041314A1
(it)
|
2004-06-30 |
2004-09-30 |
Nuvera Fuel Cells Europ Srl |
Dispositivo di raffreddamento per celle a combustibili a membrana
|
|
AR053090A1
(es)
|
2004-07-20 |
2007-04-25 |
Osi Pharm Inc |
Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
|
|
EP1794137A4
(en)
|
2004-09-27 |
2009-12-02 |
Kosan Biosciences Inc |
SPECIFIC KINASE INHIBITORS
|
|
EA200700757A1
(ru)
|
2004-09-28 |
2007-10-26 |
Янссен Фармацевтика Н.В. |
Замещённые дипиперидиновые антагонисты ccr2
|
|
SG159549A1
(en)
|
2004-11-10 |
2010-03-30 |
Cgi Pharmaceuticals Inc |
Imidazo[1,2-a] pyrazin-8-ylamines useful as modulators of kinase activity
|
|
GB0425035D0
(en)
|
2004-11-12 |
2004-12-15 |
Novartis Ag |
Organic compounds
|
|
BRPI0608840B8
(pt)
|
2005-03-07 |
2021-05-25 |
Batyer Healthcare Ag |
composição farmacêutica compreendendo uma difenil uréia substituída por ômega-carboxiarila, e seu processo de preparação
|
|
AU2006223409B2
(en)
|
2005-03-10 |
2011-07-21 |
Gilead Connecticut, Inc. |
Certain substituted amides, method of making, and method of use thereof
|
|
KR20080025039A
(ko)
|
2005-05-13 |
2008-03-19 |
아이알엠 엘엘씨 |
단백질 키나제 억제제로서의 화합물 및 조성물
|
|
PL1893612T3
(pl)
|
2005-06-22 |
2012-01-31 |
Plexxikon Inc |
Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej
|
|
US20070065449A1
(en)
|
2005-09-16 |
2007-03-22 |
Claire Verschraegen |
Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
|
|
EP1957491A2
(en)
|
2005-11-12 |
2008-08-20 |
Boehringer Ingelheim International GmbH |
Pyrrolo (2,3-b) pyridine derivatives useful as tec kinase inhibitors
|
|
MX2008008642A
(es)
|
2006-01-13 |
2008-09-12 |
Pharmacyclics Inc |
Inhibidores de las tirosina cinasas y usos de los mismos.
|
|
ES2420834T3
(es)
|
2006-01-30 |
2013-08-27 |
The Scripps Research Institute |
Métodos de detección de células tumorales circulantes y métodos de diagnóstico del cáncer en un sujeto mamífero
|
|
US20070218138A1
(en)
*
|
2006-03-20 |
2007-09-20 |
Bittorf Kevin J |
Pharmaceutical Compositions
|
|
JP2009532507A
(ja)
|
2006-04-04 |
2009-09-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Pi3キナーゼアンタゴニスト
|
|
CA2651732C
(en)
|
2006-05-18 |
2014-10-14 |
Mannkind Corporation |
Intracellular kinase inhibitors
|
|
DE102006026583A1
(de)
|
2006-06-07 |
2007-12-13 |
Bayer Healthcare Aktiengesellschaft |
Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
|
|
SI2529622T1
(en)
|
2006-09-22 |
2018-06-29 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
|
WO2008054827A2
(en)
|
2006-11-03 |
2008-05-08 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
|
NL2000640C2
(nl)
|
2007-03-05 |
2008-09-08 |
Stichting Wetsus Ct Of Excelle |
Werkwijze en systeem voor het zuiveren van een vloeistof.
|
|
US8809273B2
(en)
|
2007-03-28 |
2014-08-19 |
Pharmacyclics, Inc. |
Inhibitors of Bruton's tyrosine kinase
|
|
US20120065201A1
(en)
|
2007-03-28 |
2012-03-15 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
SG10201508035TA
(en)
|
2007-03-28 |
2015-10-29 |
Pharmacyclics Inc |
Inhibitors of bruton's tyrosine kinase
|
|
US20090010911A1
(en)
|
2007-04-06 |
2009-01-08 |
Iowa State University Research Foundation, Inc. |
Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
|
|
TWI552752B
(zh)
|
2007-10-19 |
2016-10-11 |
賽基艾維洛米斯研究股份有限公司 |
雜芳基化合物及其用途
|
|
EP2426109B1
(en)
|
2007-10-23 |
2013-12-18 |
F. Hoffmann-La Roche AG |
Novel kinase inhibitors
|
|
US8426441B2
(en)
|
2007-12-14 |
2013-04-23 |
Roche Palo Alto Llc |
Inhibitors of bruton's tyrosine kinase
|
|
US20150152115A1
(en)
|
2007-12-27 |
2015-06-04 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
CA3066426A1
(en)
|
2008-01-09 |
2009-07-16 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
|
MX2010011314A
(es)
|
2008-04-14 |
2010-11-12 |
Ardea Biosciences Inc |
Composiciones y metodos de preparacion y uso de las mismas.
|
|
EP2123626A1
(en)
|
2008-05-21 |
2009-11-25 |
Laboratorios del Dr. Esteve S.A. |
Co-crystals of duloxetine and co-crystal formers for the treatment of pain
|
|
TWI546290B
(zh)
|
2008-06-27 |
2016-08-21 |
賽基艾維洛米斯研究股份有限公司 |
雜芳基化合物及其用途
|
|
WO2010009342A2
(en)
|
2008-07-16 |
2010-01-21 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
|
|
MX2011001005A
(es)
|
2008-07-29 |
2011-09-01 |
Frontier Scient Inc |
Uso de derivados de tetraquis (n-alquilpiridinio)-porfirina para eliminacion de microbios o prevencion del crecimiento.
|
|
US8426428B2
(en)
|
2008-12-05 |
2013-04-23 |
Principia Biopharma, Inc. |
EGFR kinase knockdown via electrophilically enhanced inhibitors
|
|
WO2010068806A1
(en)
|
2008-12-10 |
2010-06-17 |
Cgi Pharmaceuticals, Inc. |
Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
|
|
US8765754B2
(en)
|
2009-04-29 |
2014-07-01 |
Locus Pharmaceuticals, Inc. |
Pyrrolotriazine compounds
|
|
RU2012114902A
(ru)
|
2009-09-16 |
2013-10-27 |
Авила Терапьютикс, Инк. |
Конъюгаты и ингибиторы протеинкиназы
|
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
|
EP3112368B1
(en)
|
2010-05-31 |
2020-02-12 |
Ono Pharmaceutical Co., Ltd. |
Purinone derivative as btk kinase inhibitor
|
|
NZ753024A
(en)
|
2010-06-03 |
2020-08-28 |
Pharmacyclics Llc |
The use of inhibitors of bruton’s tyrosine kinase (btk)
|
|
US20120071497A1
(en)
|
2010-06-03 |
2012-03-22 |
Pharmacyclics, Inc. |
Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
|
|
RU2585177C2
(ru)
|
2010-06-23 |
2016-05-27 |
Ханми Сайенс Ко., Лтд. |
Новые конденсированные пиримидиновые производные для ингибирования тирозинкиназной активности
|
|
EP2603081B1
(en)
|
2010-08-10 |
2016-10-05 |
Celgene Avilomics Research, Inc. |
Besylate salt of a btk inhibitor
|
|
US8541391B2
(en)
|
2010-10-28 |
2013-09-24 |
Viropharma Incorporated |
Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
|
|
US8501484B2
(en)
|
2011-03-14 |
2013-08-06 |
Los Alamos National Security, Llc |
Preparation of cerium halide solvate complexes
|
|
MX2011004759A
(es)
|
2011-05-04 |
2012-11-21 |
Senosiain S A De C V Lab |
Nuevas formas solidas de antibioticos.
|
|
BR112013028846B1
(pt)
|
2011-05-17 |
2021-12-07 |
Principia Biopharma Inc |
Composto ou sal farmaceuticamente aceitável do mesmo, respectivos usos, processo de preparação, intermediários e composição farmacêutica
|
|
US20140288037A1
(en)
|
2011-07-18 |
2014-09-25 |
Tokai Pharmaceuticals, Inc. |
Novel compositions and methods for treating prostate cancer
|
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
|
EP3181128B1
(en)
|
2012-01-13 |
2023-03-08 |
XSpray Pharma AB (publ) |
Nilotinib pharmaceuticalcomposition
|
|
US8501724B1
(en)
|
2012-01-31 |
2013-08-06 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
|
JP5514256B2
(ja)
|
2012-05-18 |
2014-06-04 |
株式会社東芝 |
磁気記憶素子及びその製造方法
|
|
CN104736178A
(zh)
*
|
2012-06-04 |
2015-06-24 |
药品循环公司 |
布鲁顿酪氨酸激酶抑制剂的晶形
|
|
WO2013191965A1
(en)
|
2012-06-18 |
2013-12-27 |
Principia Biopharma Inc. |
Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases
|
|
US20150140085A1
(en)
|
2012-06-29 |
2015-05-21 |
Principia Biopharma Inc. |
Formulations comprising ibrutinib
|
|
CA2879570A1
(en)
|
2012-07-24 |
2014-01-30 |
Pharmacyclics, Inc. |
Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
|
|
CN103121999A
(zh)
|
2012-08-29 |
2013-05-29 |
苏州迪飞医药科技有限公司 |
一种酪氨酸激酶抑制剂pci-32765的合成方法
|
|
KR20150084923A
(ko)
|
2012-11-15 |
2015-07-22 |
파마시클릭스, 인코포레이티드 |
키나제 억제제로서의 피롤로피리미딘 화합물
|
|
WO2014179528A2
(en)
|
2013-05-01 |
2014-11-06 |
Brown Dennis M |
Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
|
|
AU2014273946B2
(en)
|
2013-05-30 |
2020-03-12 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using PI3 kinase isoform modulators
|
|
AR097204A1
(es)
|
2013-08-02 |
2016-02-24 |
Pharmacyclics Inc |
Métodos de tratamiento de tumores sólidos
|
|
WO2015034478A1
(en)
|
2013-09-04 |
2015-03-12 |
Halliburton Energy Services, Inc. |
Scale-inhibiting cocrystals for treatment of a subterranean formation
|
|
AU2014318614B2
(en)
|
2013-09-12 |
2021-01-07 |
Dana-Farber Cancer Institute Inc. |
Methods for evaluating and treating Waldenstrom's macroglobulinemia
|
|
TWI617309B
(zh)
|
2013-10-25 |
2018-03-11 |
製藥公司 |
使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
|
|
WO2015071432A1
(en)
|
2013-11-14 |
2015-05-21 |
Sandoz Ag |
Pharmaceutical compositions of ibrutinib
|
|
CN103694241A
(zh)
|
2013-11-27 |
2014-04-02 |
苏州晶云药物科技有限公司 |
Pci-32765的新晶型a及其制备方法
|
|
CA2933900A1
(en)
|
2013-12-20 |
2015-06-25 |
Georgia Tech Research Corporation |
Formulations and methods for targeted ocular delivery of therapeutic agents
|
|
CN106008516A
(zh)
|
2014-01-29 |
2016-10-12 |
苏州晶云药物科技有限公司 |
依鲁替尼的新晶型及其制备方法
|
|
CA2938244A1
(en)
|
2014-02-07 |
2015-08-13 |
Auspex Pharamaceuticals, Inc. |
Novel pharmaceutical formulations
|
|
US20150231077A1
(en)
|
2014-02-17 |
2015-08-20 |
The Cleveland Clinic Foundation |
Amine passivated nanoparticles for cancer treatment and imaging
|
|
WO2015127261A1
(en)
|
2014-02-21 |
2015-08-27 |
Pharmacyclics, Inc. |
Biomarkers for predicting response of dlbcl to treatment with ibrutinib
|
|
US20150267752A1
(en)
|
2014-03-19 |
2015-09-24 |
Roller Bearing Company Of America, Inc. |
Bearing outer race having a radially inwardly biased seal
|
|
US9885086B2
(en)
|
2014-03-20 |
2018-02-06 |
Pharmacyclics Llc |
Phospholipase C gamma 2 and resistance associated mutations
|
|
CA2941087A1
(en)
|
2014-03-27 |
2015-10-01 |
Perrigo Api Ltd |
Ibrutinib solid forms and production process therefor
|
|
CN105085529A
(zh)
|
2014-05-15 |
2015-11-25 |
广东东阳光药业有限公司 |
依鲁替尼新晶型及其制备方法
|
|
US9127069B1
(en)
|
2014-06-11 |
2015-09-08 |
Antecip Bioventures LLC |
Compositions comprising rank/rankl antagonists and related compounds for treating pain
|
|
US20150110871A1
(en)
|
2014-06-02 |
2015-04-23 |
David Wong |
Gastric retentive tablet compositions
|
|
WO2016007617A2
(en)
|
2014-07-09 |
2016-01-14 |
Novotec Consulting, Llc. |
Pharmaceutical compounding kit
|
|
PT107846B
(pt)
|
2014-08-01 |
2019-03-22 |
Hovione Farm S A |
Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
|
|
WO2016020697A1
(en)
|
2014-08-06 |
2016-02-11 |
Cipla Limited |
Pharmaceutical compositions of polymeric nanoparticles
|
|
SG11201700849XA
(en)
*
|
2014-08-07 |
2017-03-30 |
Pharmacyclics Llc |
Novel formulations of a bruton's tyrosine kinase inhibitor
|
|
EP3180343A1
(en)
|
2014-08-14 |
2017-06-21 |
Assia Chemical Industries Ltd. |
Solid state forms of ibrutinib
|
|
EP3201197B1
(en)
|
2014-10-01 |
2019-03-27 |
ratiopharm GmbH |
Acid addition salt of ibrutinib
|
|
CN104523695A
(zh)
|
2014-11-12 |
2015-04-22 |
广东东阳光药业有限公司 |
一种治疗过度增生性疾病的药物组合物
|
|
CN105640961A
(zh)
|
2014-11-18 |
2016-06-08 |
山东瑞禾医药科技有限公司 |
一种含依鲁替尼的药物组合物
|
|
WO2016079216A1
(en)
|
2014-11-20 |
2016-05-26 |
Sandoz Ag |
Physical forms of ibrutinib, a bruton's kinase inhibitor
|
|
US20150224060A1
(en)
|
2015-01-03 |
2015-08-13 |
David Wong |
Gastric retentive tablet compositions
|
|
CZ201584A3
(cs)
|
2015-02-09 |
2016-08-17 |
Zentiva, K.S. |
Sůl Ibrutinib sulfátu
|
|
US20180051026A1
(en)
|
2015-03-03 |
2018-02-22 |
Dr. Reddy's Laboratories Limited |
Polymorphs of ibrutinib
|
|
IL315294A
(en)
|
2015-03-03 |
2024-10-01 |
Pharmacyclics Llc |
Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
|
|
US10377758B2
(en)
|
2015-04-02 |
2019-08-13 |
Ratiopharm Gmbh |
Co-crystals of ibrutinib with carboxylic acids
|
|
CN113546054A
(zh)
|
2015-04-06 |
2021-10-26 |
詹森药业有限公司 |
包含依鲁替尼的组合物
|
|
CN105294696A
(zh)
|
2015-11-19 |
2016-02-03 |
上海创诺医药集团有限公司 |
依鲁替尼新晶型及其制备方法
|
|
CN105440040B
(zh)
|
2015-12-23 |
2018-03-13 |
浙江京新药业股份有限公司 |
依鲁替尼的纯化方法
|
|
CN105646499A
(zh)
|
2016-03-01 |
2016-06-08 |
孙霖 |
依鲁替尼晶型g及制备方法
|
|
CN105646484A
(zh)
|
2016-03-01 |
2016-06-08 |
孙霖 |
晶型b及制备方法
|
|
CN105646498A
(zh)
|
2016-03-01 |
2016-06-08 |
孙霖 |
依鲁替尼晶型f及制备方法
|
|
CN106619643A
(zh)
|
2016-11-11 |
2017-05-10 |
上海雅本化学有限公司 |
一种含依鲁替尼的药物组合物
|